M4 Allosteric Modulators for Selective CNS Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction, such as schizophrenia and Alzheimer's disease, face challenges due to the lack of highly selective activators for the M4 subtype of muscarinic acetylcholine receptors, leading to adverse effects from activation of peripheral receptors.
Innovation Solution
Development of compounds that act as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4), binding to an allosteric site distinct from the orthosteric site to augment receptor activity, potentially reducing adverse effects and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AChE inhibitors are used to increase acetylcholine levels, then cognitive deficits in AD patients are improved, but cholinergic side effects such as abdominal cramps, nausea, vomiting, and diarrhea occur
Solution Approach 1:
The patent applies local quality by developing compounds with selective affinity for specific mAChR subtypes (particularly M4) rather than acting as non-selective AChE inhibitors. This subtype selectivity allows therapeutic activation of central M4 receptors while minimizing activation of peripheral M2 and M3 receptors that cause gastrointestinal side effects. The compound structure is designed to interact specifically with the M4 receptor binding site, creating a localized pharmacological effect in the central nervous system.
Solution Approach 2:
The patent segments the muscarinic acetylcholine receptor system into distinct subtypes (M1-M5) with different functional profiles. By targeting only the M4 subtype for cognitive functions while leaving other subtypes unactivated, the therapy separates the beneficial cognitive effects from the harmful peripheral cholinergic effects, thereby improving the therapeutic index.
2Reliability
If AChE inhibitors are used to treat cognitive deficits, then therapeutic efficacy is achieved, but hepatotoxicity with elevated liver transaminases occurs
Solution Approach 1:
The patent achieves local quality by directing pharmacological activity specifically to central M4 receptors rather than systemically increasing acetylcholine through AChE inhibition. This localized approach avoids the hepatic metabolism burden and toxic effects associated with conventional AChE inhibitors while maintaining cognitive therapeutic benefits.
Solution Approach 2:
The patent uses mAChR M4 positive modulators as intermediary substances that enhance M4 receptor activity without requiring increased acetylcholine production or peripheral cholinergic stimulation. This intermediary mechanism bypasses the hepatotoxic pathway of AChE inhibitors while achieving the same cognitive enhancement goal.
3Reliability
If non-selective mAChR agonists are used to activate M4 receptors, then cognitive function is improved, but adverse effects occur due to activation of peripheral mAChRs
Solution Approach 1:
The patent implements local quality through structural modifications that create compounds with preferential binding affinity for M4 receptors over other mAChR subtypes. The molecular structure is designed to fit the M4 receptor binding pocket while avoiding interaction with peripheral M2 and M3 receptors, thereby achieving central selectivity and minimizing peripheral side effects.
Solution Approach 2:
The patent segments the mAChR receptor family into functionally distinct subtypes and develops selective ligands for each. By creating M4-selective compounds, the therapy isolates the cognitive benefits of M4 activation from the peripheral effects of non-selective activation, enabling targeted therapy without cross-activation of other subtypes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide selective activation of the M4 receptor, offering potential therapeutic benefits for neurological and psychiatric disorders with reduced side effects compared to existing treatments.
Implementation Method 1
binding to an allosteric site distinct from the orthosteric site to augment receptor activity
Data Source
AI summary
Deuterium-labeled 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidines substituted with pyrrolo[3,4-b]pyridin-5-one, furo[3,4-b]pyridin-5(7H)-one, or [1,2,4]triazolo[4,3-a]pyrimidin-3(2H)-one are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.